{"id":"W2587075560","doi":"10.1182/blood.v104.11.3278.3278","title":"Antitumor Activity of Bortezomib (PS-341; Velcade) in a Phase II Study of Patients with Previously Untreated or Treated Waldenstrom’s Macroglobulinemia (WM).","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; University of Alberta Hospital; Alberta Hospital Edmonton; Juravinski Cancer Centre; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Rituximab; Waldenstrom macroglobulinemia; Gastroenterology; Macroglobulinemia; Lenalidomide; Chlorambucil; Fludarabine; Cladribine; Thalidomide; Multiple myeloma; Regimen; Lymphoplasmacytic Lymphoma; Chemotherapy; Lymphoma; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001845863,0.00124655,0.001628475,0.0004539938,0.0004430132,0.0008162226,0.0007645692,0.000792367,0.002437569],"category_scores_gemma":[0.0009411873,0.0005812936,0.0009243116,0.0004974316,0.0007298872,0.0006975955,0.0003467546,0.001943809,0.0006192942],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008829621,"about_ca_system_score_gemma":0.001063978,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009660558,"about_ca_topic_score_gemma":0.001557928,"domain_scores_codex":[0.9995894,0.0002142073,0.00002115988,0.00006350662,0.000030812,0.00008079633],"domain_scores_gemma":[0.9992686,0.0001620335,0.0001180102,0.00005554727,0.00003153791,0.0003642339],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6311204,0.1270208,0.03931836,0.00111788,0.001809634,0.001264266,0.0009199949,0.005428666,0.08935453,0.0003224666,0.003118804,0.09920411],"study_design_scores_gemma":[0.3272084,0.6070787,0.05476044,0.000044558,0.0005989696,0.0007810279,0.000128533,0.001778107,0.004614327,0.0001409536,0.002838871,0.00002715655],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9972348,0.0008576452,0.000227429,0.0001199838,0.00002872931,0.0005485839,0.0003317854,0.00002405385,0.0006270217],"genre_scores_gemma":[0.9957436,0.0008488878,0.0004915954,0.0002280643,0.0000680568,0.0006812164,0.00112828,0.00001314784,0.0007971951],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002437569,"threshold_uncertainty_score":0.009761989,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01537208609548834,"score_gpt":0.301797900612425,"score_spread":0.2864258145169367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}